Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Rubio, Marina ^a,b   Villain, Hélène ^a   Docagne, Fabian ^a   Roussel, Benoit D ^a,d   Ramos, José Antonio ^b,c   Vivien, Denis ^a   Fernandez Ruiz, Javier ^b,c   Ali, Carine ^a  

^a INSERM   (France)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DEXANABINOL; ENDOCANNABINOID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RIMONABANT; AMINO ACID RECEPTOR STIMULATING AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; N METHYLASPARTIC ACID; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; CALCIUM TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; EXCITOTOXICITY; GENE EXPRESSION; IN VITRO STUDY; LONG TERM EXPOSURE; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL CULTURE; CELL DEATH; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; NERVE CELL; WITHDRAWAL SYNDROME;

ANIMALS; CANNABINOIDS; CELL DEATH; CELLS, CULTURED; ETHANOL; EXCITATORY AMINO ACID AGONISTS; MICE; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 80051904574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023690     Document Type: Article

References (32)

1. McKeon A, Frye MA, Delanty N, (2008) The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 79: 854-862.
2. Ward RJ, Lallemand F, de Witte P, (2009) Biochemical and neurotransmitter changes implicated in alcohol-induced brain damage in chronic or 'binge drinking' alcohol abuse. Alcohol Alcohol 44: 128-35.
3. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A, (2010) Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 224: 37-47.
4. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, et al. (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70: 671-6.
5. Fernández-López D, Martínez-Orgado J, Nuñez E, Romero J, Lorenzo P, et al. (2006) Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 60: 169-73.
6. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA, (2007) Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 1128: 61-9.
7. Pertwee RG, Ross RA, (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66: 101-21.
8. Warnault V, Houchi H, Barbier E, Pierrefiche O, Vilpoux C, et al. (2007) The lack of CB1 receptors prevents neuroadaptations of both NMDA and GABA(A) receptors after chronic ethanol exposure. J Neurochem 102: 741-52.
9. Nagy J, Müller F, László L, (2001) Cytotoxic effect of alcohol-withdrawal on primary cultures of cortical neurones. Drug Alcohol Depend 61: 155-62.
10. Vinod KY, Kassir SA, Hungund BL, Cooper TB, Mann JJ, Arango V, (2010) Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr Res 44: 591-7.
11. Nagy J, Laszlo L, (2002) Increased sensitivity to NMDA is involved in alcohol-withdrawal induced cytotoxicity observed in primary cultures of cortical neurones chronically pre-treated with ethanol. Neurochem Int 40: 585-591.
12. Harper C, (2009) The neuropathology of alcohol-related brain damage. Alcohol Alcohol 44: 136-40.
13. De Witte P, Pinto E, Ansseau M, Verbanck P, (2003) Alcohol and withdrawal: from animal research to clinical issues. Neurosci Biobehav Rev 27: 189-197.
14. Maccioni P, Colombo G, Carai MA, (2010) Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. CNS Neurol Disord Drug Targets 9: 55-9.
15. Fernández-Ruiz J, (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156: 1029-40.
16. Shen M, Thayer SA, (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54: 459-62.
17. Zhuang SY, Bridges D, Grigorenko E, McCloud S, Boon A, et al. (2005) Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacol 48: 1086-96.
18. Rivers JR, Ashton JC, (2010) The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent Nerv Syst Agents Med Chem 10: 47-64.
19. Docagne F, Muñetón V, Clemente D, Ali C, Loría F, Correa F, Hernangómez M, Mestre L, Vivien D, Guaza C, (2007) Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci 34: 551-61.
20. Basavarajappa BS, Hungund BL, (1999) Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem 72: 522-8.
21. Basavarajappa BS, Hungund BL, (2002) Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. Prostaglandins, Leukot Essent Fatty Acids 66: 287-299.
22. Basavarajappa BS, Saito M, Cooper TB, Hungund BL, (2003) Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur J Pharmacol 466: 73-83.
23. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA, (2002) Changes in endocannabinoid contents in the brain of rats chronically exponed to nicotine, ethanol or cocaine. Brain Res 954: 73-81.
24. González S, Valenti M, De Miguel R, Fezza F, Fernández-Ruiz JJ, Di Marzo V, Ramos JA, (2004) Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. British Journal of Pharmacology 143: 455-64.
25. Choi DW, (1992) Excitotoxic cell death. J Neurobiol 23: 1261-1276.
26. Liu Q, Bhat M, Bowen WD, Cheng J, (2009) Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J Pharmacol Exp Ther 331: 1062-70.
27. Rubio M, McHugh D, Fernández-Ruiz J, Bradshaw H, Walker JM, (2007) Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci Lett 421l: 270-4.
28. Vinod KY, Maccioni P, Garcia-Gutierrez MS, Femenia T, Xie S, Carai MA, Manzanares J, Cooper TB, Hungund BL, Colombo G, (2011) Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. Addict Biol (in press; doi: 10.1111/j.1369-1600.2010.00299.x).
29. Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, et al. (2007) The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 36: 102-12.
30. Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, et al. (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 28: 317-24.
31. George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, et al. (2010) Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl) 208: 37-44.
32. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, et al. (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7: 59-64.